NOT FDA-APPROVED

GHRP-6

Niche use when appetite stimulation is the goal · otherwise Ipamorelin

The original ghrelin-receptor agonist. Famous mostly for one thing: it kicks up appetite, hard. Sometimes that's why people want it (cachexia, underweight athletes, muscle-gain phases). Sometimes it's why they choose Ipamorelin instead.

The 30-second read

GHRP-6 is a six-amino-acid synthetic peptide that activates the ghrelin receptor, the same receptor as Ipamorelin and GHRP-2. It was the first peptide of its class developed in the 1980s by Cyril Bowers' lab. Its defining feature is appetite stimulation: GHRP-6 activates the ghrelin pathway hard enough that hunger is essentially guaranteed within 30 minutes of dosing. That's a feature in protocols where you actually want appetite (cachexia, underweight athletes, muscle-gain phases) and a bug in everything else. It also raises cortisol and prolactin meaningfully, even more than GHRP-2. Not FDA-approved. On the FDA's Category 2 list as of September 2023. Most modern GH-secretagogue protocols skip GHRP-6 in favor of Ipamorelin's cleaner profile.

Why this peptide is on people's radar

GHRP-6 is the granddaddy of the synthetic ghrelin-receptor agonists. Cyril Bowers and colleagues developed it in the 1980s, and it's the foundation of the entire GHRP class. GHRP-2, Hexarelin, Ipamorelin, and the receptor-targeted GH secretagogue concept all came after. The historical importance is real. The clinical importance today is much smaller: GHRP-6 has been largely displaced by the cleaner Ipamorelin in modern research and longevity protocols.

Where GHRP-6 still shows up is in two specific contexts. First, protocols where appetite stimulation is intentional, cachexia (wasting from chronic illness), older patients with appetite loss, athletes in deliberate muscle-gain phases. The intense ghrelin-pathway activation that's a problem in most contexts becomes useful when you're trying to eat more, period. Second, occasional research-peptide protocols where the user specifically wants the older/cheaper option and is comfortable with the cortisol and prolactin trade-offs.

The peptide is on the FDA's Category 2 list as of September 2023, alongside the rest of the GHRP family and the GHRH-axis peptides. Modern legitimate use of GHRP-6 is uncommon enough that the conversation has shifted decisively toward Ipamorelin for most clinical purposes.

What people are usually trying to do with it

People exploring GHRP-6 are usually focused on:

Appetite stimulation, the most distinctive feature, often the actual goal
Gaining weight or muscle mass when food intake has been the limiting factor
Recovering appetite during chronic illness, post-surgery, or aging-related anorexia
An older, often cheaper alternative to newer GHRPs
A stronger ghrelin-pathway pulse than Ipamorelin produces
Combining with a GHRH analog (Sermorelin, CJC-1295) for additive GH release

What the science actually shows

GHRP-6 has decades of research behind it. The findings are well-characterized. Plain-English summary:

GH release

Reliably stimulates pulsatile GH release at standard doses. The original peptide that established the GHRP class, every later GHRP was developed against the GHRP-6 baseline.1

Appetite stimulation via ghrelin pathway

GHRP-6 produces strong, predictable appetite signals, typically intense hunger within 30–60 minutes of dosing. Effect is dose-dependent and clinically reliable.2

Cortisol and prolactin elevation

Studies confirm GHRP-6 raises cortisol, prolactin, and ACTH measurably. These elevations are larger and more consistent than with GHRP-2, and the main reason Ipamorelin became preferred for protocols where these shifts are unwelcome.3

Cardioprotective and tissue-repair signals (preclinical)

Animal studies have reported cardioprotective effects after ischemic injury and tissue-repair signaling that may be partly independent of GH release. Interesting biology; not in clinical use.4

Synergy with GHRH analogs

Like other GHRPs, GHRP-6 combined with a GHRH analog produces synergistic GH release exceeding either alone, same mechanism principle as the CJC-1295/Ipamorelin combo.

What hasn't been demonstrated

FDA approval for any indication. Long-term safety with chronic adult anti-aging use. That GHRP-6 produces meaningfully better outcomes than Ipamorelin on dimensions beyond appetite stimulation.

The honest read

What's solid:

GHRP-6's mechanism is well-characterized and the GH-release effect is reliable. The appetite effect is real and predictable. The historical importance, as the original peptide of the GHRP class, is real. For someone who specifically wants appetite stimulation alongside GH release, GHRP-6 has a defined place.

What's still being worked out:

Whether the cortisol and prolactin elevation patterns are clinically meaningful in long-term use. Whether the appetite effect (which is a lot, very fast) is sustainable or just creates eating that produces weight gain through over-consumption rather than the desired GH/IGF-1 effects.

What's hyped beyond the evidence:

GHRP-6 as a general-purpose GH peptide. For most modern use cases, better sleep, body composition support, recovery, anti-aging. Ipamorelin is the better starting point. The cortisol/prolactin shifts and intense appetite stimulation aren't features for someone trying to lose fat or maintain weight. Marketing that frames GHRP-6 as broadly equivalent to Ipamorelin overstates the case.

Things to know if you're looking into it

Almost always stacked: like other GHRPs, GHRP-6 is most commonly used paired with a GHRH analog (Sermorelin, CJC-1295 No-DAC).
How it's used in research: typically a small subcutaneous injection at night before bed, on an empty stomach. Some research-community protocols dose 2–3x daily.
Eat after dosing: the appetite kicks up within 30–60 minutes. Plan accordingly. Trying to fast through a GHRP-6 dose is unusually unpleasant.
Cortisol and prolactin caveat: a more pronounced version of the same trade-off as GHRP-2. People sensitive to those shifts should choose Ipamorelin instead.
Athlete bans: GHRP-6 is on the World Anti-Doping Agency banned list. Competitive athletes will test positive.
Regulatory status: not FDA-approved for any indication. On the FDA's Category 2 list as of September 2023.
Specific dosing protocols, mechanism, and the full reference list: all in the "Want to go deeper?" section below.

What people often ask

How is GHRP-6 different from Ipamorelin?

Same general mechanism (both activate the ghrelin receptor for GH release). GHRP-6 is older and less selective, it produces more intense appetite stimulation and notable cortisol and prolactin elevation. Ipamorelin was developed specifically to preserve GH-release activity while minimizing those side effects, which is why it's the preferred GHRP in most modern protocols.

Will it really make me hungry?

Yes, and quickly. The appetite effect is the most-noticed part of GHRP-6 use. If you're not interested in eating more, this is the wrong peptide.

Can it help with cachexia or unintended weight loss?

The appetite mechanism is theoretically aligned with that goal. Clinical use of GHRP-6 specifically for cachexia has been explored but is not an FDA-approved indication. Anyone with significant unintended weight loss or wasting should be working with a clinician for proper diagnosis and treatment.

Will it raise my cortisol?

Yes, more than GHRP-2 does and substantially more than Ipamorelin. The effect is dose-dependent. People with cortisol-related concerns (anxiety, sleep, weight pattern issues) should probably choose Ipamorelin instead.

Is it FDA-approved?

No. Not approved for any indication. On the FDA's Category 2 list as of September 2023, restricting compounding-pharmacy access.

How does it differ from GHRP-2?

Closer to each other than either is to Ipamorelin. GHRP-6 has a more pronounced appetite effect and somewhat larger cortisol/prolactin elevation than GHRP-2. GHRP-2 produces a slightly cleaner GH pulse with less appetite stimulation. Both are older-generation peptides displaced by Ipamorelin in modern protocols.

Why is it still used at all?

Three reasons: cost (often less expensive than Ipamorelin), the intentional appetite-stimulation use case, and habit in some long-running research-peptide protocols. For most adult longevity / body-composition goals, Ipamorelin is the more sensible starting point.

FDA and regulatory status

Status as of May 5, 2026: Not FDA-approved for any medical indication. On the FDA's Category 2 list as of September 2023, restricting compounding-pharmacy access under standard pathways. The April 2026 FDA advisory-committee review of compounded peptides included GHRP-6 in scope. Status updates land here when they happen.

Want to go deeper? Mechanism, half-life, dosing, side-effect profile, and references.

Background

GHRP-6 is a synthetic hexapeptide growth-hormone secretagogue. Chemical name His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂. Developed in the 1980s by Cyril Bowers and colleagues, the foundational peptide of the GHRP class. Never FDA-approved. Sold as a research peptide and used in compounded preparations through licensed pharmacies until the September 2023 Category 2 listing restricted that pathway.

Mechanism of action

GHS-R / ghrelin receptor agonism

GHRP-6 binds the GHS-R1a receptor on pituitary somatotrophs, mimicking endogenous ghrelin and triggering pulsatile GH release. Same target receptor as Ipamorelin and GHRP-2.

Less selective than Ipamorelin

GHRP-6 also strongly activates appetite signaling through the ghrelin pathway and triggers measurable cortisol, prolactin, and ACTH release. Ipamorelin was specifically engineered to preserve GH-release activity while minimizing these side-channel effects.

Half-life

Plasma half-life is approximately 15–60 minutes. The GH-pulse window after dosing is roughly 1 to 2 hours; the appetite effect can persist longer.

Synergy with GHRH analogs

Like other GHRPs, combining GHRP-6 with a GHRH analog produces synergistic GH release. Same principle as CJC-1295 / Ipamorelin combinations.

Commonly studied dosing protocols

These are not recommendations. Always consult a licensed healthcare provider before any clinical decision.

Subcutaneous (research-community range): 100 to 300 mcg per dose, typically once nightly before bed on an empty stomach. Some protocols use 2–3x daily dosing.

Stacked with a GHRH analog: commonly paired with Sermorelin or CJC-1295 (No DAC) for synergistic GH release.

Treatment duration: typical research-community cycles are 8 to 12 weeks. Long-term continuous use in healthy adults has not been formally characterized.

Side effects and safety profile

Reported in research-community use:

Intense appetite stimulation, common, reliable, the defining feature
Mild flushing or warmth shortly after injection (common, transient)
Injection-site redness or tenderness (common, mild)
Cortisol elevation (notable, dose-dependent)
Prolactin elevation (notable, dose-dependent)
Brief lightheadedness (uncommon)
Mild fluid retention (uncommon)
Sleep or mood effects related to cortisol/prolactin shifts (variable)

Theoretical concerns: GH/IGF-1 elevation interacts theoretically with cancer biology, avoid in active malignancy. Cautious use in diabetes, sleep apnea, carpal-tunnel-prone individuals, and people sensitive to cortisol or prolactin shifts.

References

Bowers CY, Momany FA, Reynolds GA, Hong A. (1984). "On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone." Endocrinology, 114(5), 1537–1545. PubMed
Wren AM, Small CJ, Ward HL, et al. (2000). "The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion." Endocrinology, 141(11), 4325–4328. PubMed
Sigalos JT, Pastuszak AW. (2018). "The safety and efficacy of growth hormone secretagogues." Sex Med Rev, 6(1), 45–53. PubMed
Berlanga J, Cibrian D, Guevara L, et al. (2002). "Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction." Clin Sci, 103(suppl 48), 423S–426S. PubMed
U.S. Food and Drug Administration. (2023). "Pharmacy Compounding Guidance. FDA Category 2 List." FDA.gov

For educational and research purposes only. This is not medical advice. GHRP-6 is not FDA-approved and is on the FDA's Category 2 list as of September 2023. Consult a licensed healthcare provider before considering any peptide. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does.